| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in AustraliaTGA Approves NexoBrid® for Adults and Children;...
MediWound (NASDAQ:MDWD) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.57) b...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and raises the price tar...
MediWound (NASDAQ:MDWD) sees FY2025 sales of $24.000 million vs $23.97 million analyst estimate.
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.66) by ...